IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
IMUNON announced updated final data from its Phase 2 OVATION 2 trial showing that treatment with IMNN-001 combined with standard chemotherapy significantly improved median overall survival in women with newly diagnosed advanced ovarian cancer, especially when combined with PARP inhibitors. Enrollment in the pivotal Phase 3 OVATION 3 trial is ahead …